Differentiation Syndrome (DS), also known as retinoic acid syndrome (RAS), is a potentially life-threatening complication that can occur in patients undergoing treatment with differentiating agents, particularly in acute promyelocytic leukemia (APL).
Key Features:
- Caused by:
- Drugs like all-trans retinoic acid (ATRA) or arsenic trioxide (ATO), which induce differentiation of leukemic promyelocytes into mature neutrophils.
- Mechanism:
- Rapid release of cytokines from differentiating cells leads to systemic inflammation, capillary leak, and organ infiltration.
- Onset:
- Typically occurs within days to weeks after starting therapy.
Symptoms & Signs:
- Fever (without infection)
- Dyspnea (respiratory distress, pulmonary infiltrates, pleural/pericardial effusions)
- Hypotension (due to capillary leak)
- Weight gain (fluid retention, edema)
- Renal dysfunction (due to hypoperfusion)
- Leukocytosis (high white blood cell count)
Management:
- High-dose glucocorticoids (e.g., dexamethasone) to suppress inflammation.
- Temporary interruption of the differentiating agent (ATRA/ATO) in severe cases.
- Supportive care (oxygen, diuretics, IV fluids, monitoring for organ failure).
- Prophylactic steroids may be used in high-risk patients.
Why It’s Important:
- Can progress rapidly to respiratory failure, renal failure, or shock if untreated.
- Early recognition and steroid therapy are critical.
In the provided case, LJ’s symptoms align with DS, justifying the use of glucocorticoids while continuing APL treatment. Other possibilities (e.g., pulmonary embolism, infection) were considered but deemed less likely.